Free Trial
→ The End of Elon Musk…? (From Brownstone Research) (Ad)
NASDAQ:MTSR

Metsera 3/26/2025 Earnings Report

Metsera logo
$43.73 +0.75 (+1.74%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Metsera EPS Results

Actual EPS
-$3.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Metsera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Metsera Announcement Details

Quarter
Date
3/26/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Metsera Earnings Headlines

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association
July 14 at 11:20 AM  |  finance.yahoo.comhttps://finance.yahoo.com/news/metsera-mtsr-presented-85th-scientific-115225621.html
Metsera Clears Key Benchmark, Hitting 90-Plus RS Rating
July 9, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/metsera-clears-key-benchmark-hitting-90-plus-rs-rating/ar-AA1Ih0rh
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
July 16 at 2:00 AM  |  Brownstone Research (Ad)
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Nasdaq
June 26, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/wall-street-analysts-see-8966-upside-metsera-inc-mtsr-can-stock-really-move-high
Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation
June 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/wells-fargo-initiates-coverage-of-metsera-mtsr-with-overweight-recommendation/ar-AA1H7e7r
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review
June 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4794410-promising-results-of-amylin-analogs-in-obesity-metsera-case-review
See More Metsera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email.

About Metsera

Metsera (NASDAQ:MTSR), Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

View Metsera Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles